Literature DB >> 14535502

Characterization of endogenous retroviruses in pig cell cultures.

M Ferrari1, M N Losio, A Corradi, S Vittori, A Tosini.   

Abstract

Entities:  

Mesh:

Year:  2003        PMID: 14535502     DOI: 10.1023/b:verc.0000014252.67459.6d

Source DB:  PubMed          Journal:  Vet Res Commun        ISSN: 0165-7380            Impact factor:   2.459


× No keyword cloud information.
  7 in total

1.  Antiretroviral agents inhibit infection of human cells by porcine endogenous retroviruses.

Authors:  S K Powell; M E Gates; G Langford; M L Gu; C Lockey; Z Long; E Otto
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

2.  Comparison of replication-competent molecular clones of porcine endogenous retrovirus class A and class B derived from pig and human cells.

Authors:  U Krach; N Fischer; F Czauderna; R R Tönjes
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

3.  AGAR SUSPENSION CULTURE FOR THE SELECTIVE ASSAY OF CELLS TRANSFORMED BY POLYOMA VIRUS.

Authors:  I MACPHERSON; L MONTAGNIER
Journal:  Virology       Date:  1964-06       Impact factor: 3.616

4.  Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living pig tissue. The XEN 111 Study Group.

Authors:  K Paradis; G Langford; Z Long; W Heneine; P Sandstrom; W M Switzer; L E Chapman; C Lockey; D Onions; E Otto
Journal:  Science       Date:  1999-08-20       Impact factor: 47.728

5.  Infection of human cells by an endogenous retrovirus of pigs.

Authors:  C Patience; Y Takeuchi; R A Weiss
Journal:  Nat Med       Date:  1997-03       Impact factor: 53.440

6.  Two sets of human-tropic pig retrovirus.

Authors:  P Le Tissier; J P Stoye; Y Takeuchi; C Patience; R A Weiss
Journal:  Nature       Date:  1997-10-16       Impact factor: 49.962

7.  Host range and interference studies of three classes of pig endogenous retrovirus.

Authors:  Y Takeuchi; C Patience; S Magre; R A Weiss; P T Banerjee; P Le Tissier; J P Stoye
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.